Loading
A phase 2 trial of IMC-001 run by Asan Medical Center, active and no longer recruiting.
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers is a phase 2 interventional study registered as NCT04196465 by Asan Medical Center, with 48 participants planned, started 2019-09-09. Conditions recorded: Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer and Subjects With Resectable Liver Cancer. Interventions recorded: IMC-001.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/